C
1.33
-0.10 (-6.96%)
| 前收盘价格 | 1.43 |
| 收盘价格 | 1.40 |
| 成交量 | 7,665 |
| 平均成交量 (3个月) | 110,303 |
| 市值 | 20,613,170 |
| 价格/销量 (P/S) | 0.710 |
| 股市价格/股市净资产 (P/B) | 11.21 |
| 52周波幅 | |
| 利润日期 | 14 Aug 2025 - 18 Aug 2025 |
| 营业毛利率 | -129.05% |
| 营业利益率 (TTM) | -163.99% |
| 稀释每股收益 (EPS TTM) | -2.54 |
| 季度收入增长率 (YOY) | 83.00% |
| 总债务/股东权益 (D/E MRQ) | 1,196.16% |
| 流动比率 (MRQ) | 0.810 |
| 营业现金流 (OCF TTM) | -29.22 M |
| 杠杆自由现金流 (LFCF TTM) | -15.22 M |
| 资产报酬率 (ROA TTM) | -50.88% |
| 股东权益报酬率 (ROE TTM) | -1,094.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | CASI Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-0.5
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.50 |
|
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 43.76% |
| 机构持股比例 | 23.64% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Foresite Capital Management Vi Llc | 31 Mar 2025 | 1,329,383 |
| Wellington Shields Capital Management, Llc | 31 Mar 2025 | 90,894 |
| Wellington Shields & Co., Llc | 31 Mar 2025 | 30,091 |
| 52周波幅 | ||
| 中 | 4.00 (200.64%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 May 2025 | 4.00 (200.64%) | 购买 | 1.91 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合